Crinetics Pharmaceuticals Inc.

CRNX

Held by 12 specialist biotech funds

High Convergence

12 funds opened new positions. Next phase2 readout (atumelnant): Oct 2026. Short interest: 7.3% of float.

BiotechnologyCEO: R. Scott StruthersIPO: 2018Website ↗

Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.

Catalysts

Phase 2ApprovedQ3 2020PaltusotineAcromegalyNCT03792555

Primary: Responder Criteria Was Based on the Mean of Two Consecutive Insulin-like Growth Factor-1 [IGF-1] Measurements ≤ULN at Week 13 (13 Weeks)Enrollment:13/13Sites: 11RANDOMIZED, TRIPLE, TREATMENT

Phase 2ApprovedQ3 2020PaltusotineAcromegalyNCT03789656

Primary: Change From Baseline (Median of Screening Values) in Insulin-like Growth Factor-1 (IGF-1) Level (13 Weeks)Enrollment:47/47Sites: 26NA, TREATMENT

Phase 3ApprovedQ3 2023PaltusotineAcromegalyNCT04837040

Primary: Percentage of Participants Who Maintain Biochemical Response in IGF-1 (≤1.0× the Upper Limit of Normal [ULN]) at the End of the Randomized Control Phase (EOR) (36 Weeks)Enrollment:58/58Sites: 39RANDOMIZED, DOUBLE, TREATMENT

Phase 3ApprovedQ1 2024PaltusotineAcromegalyNCT05192382

Primary: Percentage of Participants With a Biochemical Response in Insulin-like Growth Factor-1 (IGF-1) at the End of the Randomized Control Phase (EOR) (Week 24)Enrollment:111/111Sites: 57RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q1 2024Randomized: 40 mg PaltusotineCarcinoid Syndrome, Carcinoid, Carcinoid TumorNCT05361668

Phase 2Q3 2025atumelnant (CRN04894)Congenital Adrenal Hyperplasia, Classic Congenital Adrenal HyperplasiaNCT05907291

Phase 2Q4 2026atumelnantCushing Syndrome, Cushing Disease, Ectopic ACTH SyndromeNCT05804669

Primary: Proportion of participants with treatment emergent adverse events (TEAEs) (Up to Day 15)Enrollment:19/19Sites: 1NA, TREATMENT

Phase 3Q2 2027AtumelnantCongenital Adrenal Hyperplasia, Classic Congenital Adrenal HyperplasiaNCT07144163

Phase 3Q3 2027PaltusotineCarcinoid Syndrome, Carcinoid, Carcinoid TumorNCT07087054

Phase 2Q3 2027CRN09682SST2-positive Neuroendocrine Neoplasms, Neuroendocrine Tumors, Neuroendocrine NeoplasmNCT07129252

Phase 2Q3 2029atumelnant (CRN04894)Congenital Adrenal Hyperplasia, Classic Congenital Adrenal HyperplasiaNCT06712823

Phase 3Q1 2030AtumelnantCongenital Adrenal Hyperplasia, Classic Congenital Adrenal HyperplasiaNCT07159841

Primary: Change from baseline in morning serum androstenedione (A4) (Part A) (Week 8)Enrollment:Target 153Sites: 48RANDOMIZED, TRIPLE, TREATMENT

Crinetics Pharmaceuticals Inc.

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Activist Filings

Recent News & Research

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research